All Studies · Cognition & Neurodegeneration · Oughli (2025)

Oughli (2025)

Moderate · RCT Secondary Analysis · Secondary Analysis (RCT-derived) · n = 56
Quality Index (Adjusted QI) 0.762
0 Low < 0.56 Moderate 0.56–0.77 High ≥ 0.78 1
Study Details
ConditionSubjective cognitive decline + AD peripheral biomarkers
Clinical domainCognition & Neurodegeneration
PopulationPostmenopausal women (≥50 yrs) with SCD and cardiovascular risk factors
Sample sizen = 56
Country / SettingUSA (UCLA, Los Angeles, CA)
Protocol clusterKirtan Kriya (12-min)
Duration12 weeks KY vs MET; biomarker data at baseline and 24-week follow-up (same trial as Grzenda 2025, NCT03503669)
Control typeActive Control
ComparatorMemory Enhancement Training (MET); same comparator as Grzenda 2025
Outcomes & Effect Sizes
Primary outcomeAD biomarkers (Aβ40, Aβ42, p-tau) + Subjective memory
Scales usedPlasma Aβ40, Aβ42, Aβ42/40 ratio, p-tau; Memory Functioning Questionnaire (MFQ) Frequency of Forgetting and Seriousness of Forgetting subscales
Key resultNo significant group differences in AD biomarkers at baseline or 24-week follow-up. Higher baseline Aβ40 and Aβ42 significantly associated with improvement in subjective memory (MFQ). No association of Aβ42/40 ratio or p-tau with memory change.
Effect sizeNo significant group differences in biomarkers; baseline Aβ40/Aβ42 predicted memory improvement
Retention56/79 (71%) had biomarker data at both timepoints (KY=24/40, MET=32/39)
SafetyNot separately reported (see Grzenda 2025 parent trial)
View PDF
Methodological Summary

Secondary analysis of RCT (NCT03503669); biomarker subsample N=56; exploratory; peripheral blood AD markers; UCLA single-site

KY Protocol Components

AD Biomarker Analysis from KY vs MET Trial (NCT03503669 — Secondary Analysis) PARENT TRIAL: Same RCT as Grzenda 2025 — 79 women with SCD and cardiovascular risk factors randomized to KY (n=40) vs MET (n=39). BIOMARKER SUBSAMPLE: N=56 with available blood samples (KY=24, MET=32) at baseline and 24-week follow-up. INTERVENTION: Same as Grzenda 2025 — 12 weeks of weekly 60-min KY classes + daily 12-min Kirtan Kriya. BIOMARKERS MEASURED: Peripheral blood — Aβ40, Aβ42, Aβ42/40 ratio, phosphorylated-tau (p-tau). SUBJECTIVE MEMORY: Memory Functioning Questionnaire (MFQ) — Frequency of Forgetting, Seriousness of Forgetting. KEY FINDING: No significant group differences or changes in AD biomarkers. However, higher baseline Aβ40 and Aβ42 levels predicted improvement in subjective memory at follow-up. NOTE: Exploratory biomarker analysis from the same parent trial as Grzenda 2025.

Quality Item Scores — 1 fail · 2 partial · 3 pass · ★ critical
★A1
3
A2
3
★B1
2
★B2
2
B3
3
B4
2
★B5
2
B6
3
★B7
2
★B8
2
B9
2
JP1
3
Critical fails0
Raw QI0.806
SAF0.946
Adjusted QI0.762
Final ratingModerate